Sol-Gel Technologies (SLGL) Share-based Compensation (2017 - 2025)
Sol-Gel Technologies (SLGL) posted quarterly Share-based Compensation of $100000.0 for Q2 2025, down 63.64% year-over-year from $275000.0 in Q2 2024, and down 63.64% quarter-over-quarter from $275000.0 in Q2 2024.
Sol-Gel Technologies (SLGL) Share-based Compensation (2017 - 2025) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Share-based Compensation for 8 consecutive years, with $100000.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Share-based Compensation fell 63.64% year-over-year to $100000.0; the TTM figure through Jun 2025 stood at $1.2 million (down 8.45% YoY), while the FY2025 annual figure was $82000.0, down 89.57% from the prior year.
- Share-based Compensation slipped to $100000.0 in Q2 2025 per SLGL's latest filing, from $275000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $498000.0 in Q2 2023 and bottomed at $100000.0 in Q2 2025.
- Historically, Share-based Compensation has averaged $287600.0 across 5 years, with a median of $275000.0 in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 65.26% — and 2025, when it slumped 63.64%.
- Sol-Gel Technologies' Share-based Compensation stood at $213000.0 in 2021, then surged by 65.26% to $352000.0 in 2022, then surged by 41.48% to $498000.0 in 2023, then slumped by 44.78% to $275000.0 in 2024, then plunged by 63.64% to $100000.0 in 2025.
- Business Quant data shows SLGL's Share-based Compensation at $100000.0 in Q2 2025, $275000.0 in Q2 2024, and $498000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2024 | 275,000.00 |
| Jun 30, 2024 | 275,000.00 |
| Jun 30, 2023 | 498,000.00 |
| Jun 30, 2023 | 498,000.00 |
| Jun 30, 2022 | 352,000.00 |
| Jun 30, 2022 | 352,000.00 |
| Jun 30, 2021 | 213,000.00 |
| Jun 30, 2021 | 213,000.00 |
| Jun 30, 2020 | 315,000.00 |
| Jun 30, 2020 | 315,000.00 |
| Dec 31, 2018 | 2.93 Mn |
| Dec 31, 2018 | 2.93 Mn |
| Dec 31, 2017 | 7.16 Mn |
| Dec 31, 2017 | 7.16 Mn |